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MOPPEBVCADChemotherapy with Limited and Conditioned
Radiotherapy in Advanced Hodgkin’s Lymphoma: 10-Year
Results, LateToxicity, and SecondTumors
Paolo G. Gobbi,1Chiara Broglia,1Alessandro Levis,3 Antonio La Sala,4 FrancescoValentino,1
Teodoro Chisesi,5 Stefano Sacchi,6 Franco Corbella,2 Luigi Cavanna,9 Emilio Iannitto,8
Vincenzo Pavone,10 StefanoMolica,11Gino Roberto Corazza,1andMassimo Federico7
Abstract Purpose:MOPPEBVCAD (mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubi-
cin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine) chemotherapy with limited
radiotherapy was devised in1987 to reduce late toxicity and second tumor incidencewhile trying
to improve effectiveness through increases of dose intensity and dose density. Late results, toxic-
ity, and second tumor incidencewere reviewed in all the patients treated.
Experimental Design: The drugs of three previous alternating regimens [CAD (lomustine,
melphalan, and vindesine), MOPP (mechlorethamine, vincristine, procarbazine, and prednisone),
and ABV (doxorubicin, bleomycin, and vinblastine)] were intensified and hybridized, the cumu-
lative dose of mechlorethamine was lowered, and irradiation was delivered to no more than two
sites either bulky or partially responding to chemotherapy.
Results:A total of 307 previously untreated advanced-stage patients underwentMOPPEBVCAD
chemotherapy. Radiotherapy was delivered to 118 of 307 patients (38%). Remission was com-
plete in 290 patients (94%).With amedian follow-up of114months,10-year overall, disease-free,
and failure-free survival rates were 79%, 84%, and 71%, respectively. Forty-two patients relapsed
and 60 died.The causes of deathwere Hodgkin’s lymphoma in 36 patients, second neoplasms in
12, cardiorespiratory diseases in 4, pulmonary diseases in 2, and unknown in 6. Sixteen second
tumors (of whichnineweremyelodysplasia and/or acute leukemia)were diagnosed in all. Outside
this series of 307patients,MOPPEBVCADobtained complete responses in12 of15 relapsedand9
of 9 refractory patients whohad previously been treatedwith other regimens.
Conclusions: Clinical response and long-term results are very satisfactory, whereas the second
tumor incidence was lower than would have been expected with MOPP analogues. Given its
response/late toxicity balance, MOPPEBVCAD does not undermine the leading role of ABVD as
first-line regimen but can be indicated as a very effective second-line conventional therapy.
In the last few decades, Hodgkin’s lymphoma has passed from
being a fatal disease to being one of the most curable human
cancers. However, despite this clinical progress, 20% to 30% of
patients progress or relapse. Furthermore, long-term survivors
are still at risk of late treatment–related complications, such as
cardiac or pulmonary dysfunction, infertility, thyroid-related
sequelae, or second tumors. The malignancies most frequently
associated with chemotherapy include acute myeloid leukemia
and myelodysplastic syndrome (AML/MDS), whereas the use of
radiation therapy is related to a constantly increasing risk of
second solid tumors.
The standard chemotherapy combination for advanced
Hodgkin’s disease was MOPP (mechlorethamine, vincristine,
procarbazine, and prednisone) in the 1970s and 1980s and for
the last 15 years has been ABVD (doxorubicin, bleomycin,
vinblastine, and dacarbazine). A mathematical model devised
by Goldie and Coldman (1) relating the drug sensitivity of
tumor cells to the spontaneous mutation rate of cells led many
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investigators, particularly between 1980 and 1990, to design
new chemotherapy schedules that either alternated some of
the most effective regimens in use [i.e., MOPP/ABVD (2),
MOPP/CABS (CCNU, doxorubicin, bleomycin, and streptozo-
cin) (3), MOP-BAP (bleomycin, doxorubicin, and procarba-
zine) (4), MOPP-CAVmP (cyclophosphamide, doxorubicin,
teniposide, and metilprednisolone) (5), and BCVPP (BCNU,
vinblastine, cyclophosphamide, procarbazine, and predni-
sone)/ABD (doxorubicin, bleomycin, and decarbazine) (6)]
or hybridized them by delivering in each cycle all the drugs
scheduled in different regimens [MOPP/ABV (7), MA/MA
(MOPP on day 1, ABVD on day 15 of each monthly cycle)
(8), ChlVPP (chlorambucil, vinblastine, procarbazine, and
prednisone)/EVA (etoposide, vincristine, and doxorubicin)
(9)]. More recently, a statistical model by the German Hodgkin
Study Group, which considers tumor growth and chemother-
apy effects (10), indicated that intensifying drug doses through
considerable dose escalation could be the best choice: The
result of this theory was the BEACOPP (bleomycin, etoposide,
Adriamycin, cyclophosphamide, vincristine, procarbazine, and
prednisone) schedule (11, 12).
However, in 1987, in agreement with the then contemporary,
evolving basic criteria of chemotherapy for advanced Hodgkin’s
lymphoma, the Italian Lymphoma Study Group [Gruppo
Italiano per lo Studio dei Linfomi (GISL)] designed a
shortened, hybridized, and intensified version of Straus’
alternating regimen, CAD/MOPP/ABV (13), and combined it
with a restricted use of radiotherapy, which was limited to sites
of bulky involvement or to areas that had not responded
completely to chemotherapy. The basic idea underlying the
formulation of the MOPPEBVCAD regimen was to improve an
already existing treatment program, widely tested and highly
effective, by introducing selected chances. The hybridization of
the drugs of alternating CAD/MOPP/ABV into the MOPPEBV-
CAD schedule complied more closely with Goldie and Cold-
man’s (1) theory. Moreover, the adopted modification of the
original schedule seemed to partially accomplish the improve-
ments indicated by Norton and Simon’s (14) model, at least as
far as the dose density was concerned. The contemporary
increase of dose intensity and dose density was obtained for
the majority of drugs by administering in six cycles approxi-
mately the same cumulative drug dosage delivered with the
original nine cycles of the alternating CAD/MOPP/ABV and by
reducing the cycle length from 35 to 28 days. The total dose of
mechlorethamine was reduced by 50%. The delivery of radio-
therapy was limited and conditioned to the presence of no
more than two areas with either an original bulky mass and/or
a lesion incompletely remitting after chemotherapy.
The early data on feasibility, toxicity, and short-term results
of this modified chemotherapy program, collected in different
trials, were encouraging (15–18). We report here the cumula-
tive experience—with particular attention to late results and
toxicity—achieved in all the patients evaluated in those original
studies.
Patients andMethods
Patients. In this study, we reviewed and updated the clinical
information regarding all those patients treated with MOPPEBVCAD
chemotherapy plus limited radiotherapy who were enrolled and
considered eligible in the three distinct clinical trials that administered
this combined therapy in at least one treatment arm. The population of
the present study, therefore, comprised the 145 patients enrolled in a
controlled, open, nonrandomized study carried out by the GISL (15,
16) between 1988 and 1993, together with 24 patients evaluated in a
prior, unpublished pilot study carried out during 1987, the 32 patients
randomized to MOPPEBVCAD—with or without radiotherapy—in a
second GISL study (17) conducted from 1994 to 1995, and, finally, the
106 subjects randomized to the same treatment in a randomized trial of
the Intergruppo Italiano Linfomi (18) between 1996 and 1999. In the
second GISL study (17), the MOPPEBVCAD regimen was compared
against a variant in which cyclophosphamide substituted lomustine and
etoposide substituted melphalan (MOPPEBVCyED). In the Intergruppo
Italiano Linfomi trial (18), patients were randomized into three
different treatment arms—MOPPEBVCAD, ABVD, and Stanford V
chemotherapy. In all these studies, the criteria adopted for administra-
tion of radiation therapy did not differ.
Enrollment requirements, staging procedures, and treatment criteria
were the same in the three trials and were detailed in each study report.
Synthetically, unequivocal histology of Hodgkin’s lymphoma, age
between 15 years and an upper limit varying from 65 to 75 years
according to the trial, no previous treatment and clinical stage IIB, III, or
IV were necessary for entry to the study. Staging was evaluated
according to the recommendations of the Cotswolds Meeting (19); in
particular, all patients underwent computed tomography of the thorax,
abdomen, and pelvis and had a bone marrow core biopsy taken from
one iliac spine only.
A total of 307 patients (enrolled from 1988 to 1999) were eligible for
the evaluation presented here. The clinical characteristics of these
patients are listed in Table 1.
Chemotherapy. The drug doses and time schedule of the MOPPEBV-
CAD hybrid regimen are listed in Table 2. Six cycles of chemotherapy
were planned. Growth factors were not available before 1992 in Italy and
after that time were not permitted routinely, but used only in cases of
severe neutropenia (< 0.5 109/L) associated with fever or other signs of
infection. When growth factors were necessary, they were administered in
the shortest period included in the restricted time interval from day 16 to
25 of the whole regimen.
In potentially fertile young women who did not have specific
contraindications, ovulation was suppressed throughout the treatment
with third-generation progestins (desogestrel and gestodene) or with
triphasic estrogen-progestin combinations.
Radiotherapy. This was not routinely associated with chemotherapy
but was administered only to patients who presented bulky masses
(according to the Cotswolds Meeting criteria) at their staging evaluation
or had involved sites that showed only partial response after
chemotherapy. Treatment with radiotherapy was possible only on
condition that no more than two lymph node areas fulfilled the above
requirements. This led to a minority of patients in each clinical trial
undergoing radiation therapy, precisely 32% (15, 16), 37% (17), and
47% (18) in the three trials, respectively, corresponding to an average
38% of the whole series of 307 cases. Radiotherapy had to start 4 to 6
weeks after the end of chemotherapy. The recommended total doses
were 36 Gy to areas with no signs of disease at the end of chemotherapy
[cases with bulky masses in complete remission (CR) or unconfirmed
remission] and 42 Gy to sites with partially persisting disease. Volumes
of radiotherapy as well as technical equipment were possibly different
in the distinct radiotherapy units involved in the trials.
Assessment of response and statistical analysis. Residual lesions after
treatment were evaluated by 67Ga scintigraphy and computed
tomography, and, more recently, through positron emission tomogra-
phy. CR was defined as complete regression of measured lesions and
disappearance of the other objective signs and symptoms of lymphoma
for at least 3 months. Partial remission corresponded to a decrease of
>50% in the sum of the products of the diameters of the measurable
lesions with disappearance of any symptom. Progressive disease was
defined as a z25% increase in the size of at least one measurable lesion,
or the appearance of a new lesion or recurrence of constitutional
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symptoms. No response was variation of the measurable lesions
ranging from that of partial remission to that of progressive disease.
Toxicity was measured according to standard Eastern Cooperative
Oncology Group criteria (20).
Dose intensity was calculated according to the criteria reported by
Hryniuk (21) and examples and suggestions offered by De Vita et al. (22).
Overall survival was determined from the date of diagnosis to
the date of last observation or death (from any cause). Disease-free
survival for complete responders was measured from the date of
therapy completion to the date of last observation or relapse. Failure-
free survival was computed from the start of treatment to one of the
following events: death from disease or treatment, disease progression,
or relapse. Survival curves were calculated on a intention-to-treat basis
using the method of Kaplan and Meier (23, 24). Standard m2 test and
ANOVA (25) were used to evaluate the distribution of clinical
characters, biochemical values, response variables, and toxicity grades
among the groups of patients of each original trial.
Results
A total of 1,751 cycles of MOPPEBVCAD were administered
in 307 patients (mean number of cycles per patient: 5.6, range
3-8) with a 0.73 F 0.12 mean relative dose intensity, which
showed minimal variations among the four distinct multicenter
studies as detailed in Table 3 (0.72 F 0.11, 0.75 F 0.13, and
0.73 F 0.14).
Although complete information on the acute toxicity was
given in the original trial reports (15 – 18), we should
emphasize that hematologic toxicity, mainly neutropenia and
thrombocytopenia, was the major factor that limited the dose
intensity actually administered (Table 4). Seventy-four subjects
(24%) received granulocyte colony-stimulating factor for at
least a few days and the cumulative dose intensity of
Table1. Clinical characteristics of the patients at diagnosis
GISL IIL Total
Pilot Nonrandomized Randomized Randomized
1987 1988-1993 1994-1995 1996-1999 1987-1999
Patient no. 24 145 32 106 307
Male/female 11/13 85/60 15/17 55/51 166/141
Age (y), median (range) 29 (17-59) 35 (16-75) 33 (16-69) 34 (15-65) 34 (16-75)
Histology*
LP 0 1 1 7 9
NS 17 88 21 66 192
MC 2 42 8 26 78
LD 1 12 1 2 16
Unclassified 4 2 1 5 12
Stage*
IIB 6 45 9 26 86
IIIA 7 22 5 23 57
IIIB 2 39 6 32 79
IVA 8 11 6 11 36
IVB 1 28 6 14 49
Karnofsky index, median (range) 80 (40-100) 80 (50-100) 80 (60-100) 80 (50-100) 80 (40-100)
Bulky disease* 4 47 5 19 75
Bonemarrow involvement 4 22 4 12 40
Hemoglobin (g/L), mF SD 102F 22 119F 20 114F18 107F19 113F 20
Serum LDH (units/L), mF SD 586F 266 400F 225 352F 185 515F 196 449F 192
Serum albumin (g/L), mF SD 30.5F 8.2 36.4F 5.9 39.0F 6.1 32.3F 7.1 34.8F 6.8
ESR (mm/1st h), median (range) 66 (8-148) 62 (7-133) 59 (5-113) 56 (7-121) 60 (5-140)
WBC (109/L), mF SD 13.4F 9.1 11.3F 7.9 13.6F10.8 13.4F 8.6 12.5F 9.3
Abbreviations: IIL, Intergruppo Italiano Linfomi; LP, lymphocyte predominance; NS, nodular sclerosis; MC, mixed cellularity; LD, lymphocyte depletion; mF SD, arith-
metic meanF1SD; ESR, electron spin resonance.
*P < 0.0500 for the distribution of the characteristic among the four groups, m2 test.
Table 2. Drug doses and time schedule of
MOPPEBVCAD regimen
Drugs mg/m2 Route Days
Mechlorethamine 6 i.v. 1 (cycles1, 3, and 5, only)
Lomustine 100 oral 1 (cycles 2, 4, and 6, only)
Vindesine 3 i.v. 1
Melphalan 6 oral 1-3
Prednisone 40 oral 1-14
Epidoxorubicin 40 i.v. 8
Vincristine 1.4 i.v. 8
Procarbazine 100 oral 8-14
Vinblastine 6 i.v. 15
Bleomycin 10 i.v. 15
MOPPEBVCAD in Advanced Hodgkin’s Lymphoma
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chemotherapy in these patients was slightly lower than that in
patients who did not require growth factors (0.72F 0.09 versus
0.74 F 0.11). Nonhematologic toxicity was acceptable and
generally well controlled. In particular, neurotoxicity was
relatively frequent but was fully tolerable in spite of the three
distinct Vinca derivatives included in the schedule.
Table 3 reports the clinical outcome besides some therapeutic
details. Response after chemotherapy was complete in 238
patients (78%), partial in 64 (21%), and null in 5 (2%).
Radiotherapy was administered to 118 patients (38%), 64 of
whom had at least one partially remitting lesion. The mean
interval between the end of chemotherapy and the start of
radiotherapy was 5 weeks. Radiation doses ranged from 26 to
44 Gy (mean F SD: 37.3 F 5.6).
After chemotherapy and radiotherapy, when delivered, 290
patients achieved CR (94%), 12 obtained only partial remission
(4%), and the remaining 5 did not respond at all (2%). Forty-two
patients of the 290 complete responders relapsed at variable
intervals after the cessation of therapy (from 3 to 104 months).
Fifteen of them underwent high-dose chemotherapy followed
by peripheral blood stem cell transplantation (nine patients
achieved a CR, four a partial remission, and two had no
response); six further patients were rescued to CR by means of
extended radiotherapy programs; the remaining 21 cases were
treated with other chemotherapy regimens and only four of them
reached a second CR.
Thus far, 60 patients have died. The causes of death were
Hodgkin’s disease in 36 patients (early treatment-related
death, progression after either first-line chemotherapy failure,
or one or more relapses), a second neoplasm in 12,
cardiorespiratory disease in 4, pulmonary disease in 2, and
unknown in 6. In particular, among the fatal, acute, treatment-
related adverse effects, there was one case of progressive
multifocal leucoencephalopathy, one of fatal gastric hemor-
rhage during serious pancytopenia, and one sudden cardiac
death.
With a median follow-up of 114 months (range 20-197), 10-
year overall, disease-free, and failure-free survival rates were
79%, 84%, and 76%, respectively (Fig. 1).
With regard to second neoplasms, nine patients (2.9%)
developed a secondary AML/MDS. Five of them were treated
with MOPPEBVCAD only, four also with combined radio-
therapy, and two of these last had additional chemotherapy
for relapse. Solid tumors were recorded in four patients
Table 3. Parameters of therapy and clinical outcome
Study GISL IIL
Pilot
(1987)
Nonrandomized
(1988-1993)
Randomized
(1994-1995)
Randomized
(1996-1999)
Total
(1987-1999)
No. patients 24 145 32 106 307
No. cycles 119 844 179 609 1,751
Mean (range) 5.0 (3-6) 5.8 (3-8) 5.6 (3-6) 5.7 (4-6) 5.6 (3-8)
Cumulative DI, meanF SD 0.77F 0.15 0.72F 0.11 0.75F 0.13 0.73F 0.14 0.73F 0.12
Response to CT
CR 18 112 26 82 238
PR 6 29 5 24 64
NR 0 4 1 0 5
RT 8/24 47/145 13/32 50/106 118/307
Interval CT-RT (d), mean (range) 31 (20-42) 33 (22-47) 33 (23-42) 42 (24-48) 36 (20-48)
Response to CT (+RT)
CR 21 137 32 100 290
PR 2 4 0 6 12
NR 1 4 0 0 5
Abbreviations: DI, dose intensity; CT, chemotherapy; RT, radiotherapy; PR, partial remission; NR, null response.
Table 4. Percentages of grades 3 and 4 acute toxicity
in the 307 patients
Study ECOG grades 3/4
GISL IIL Total
1987 1988-1993 1994-1995 1996-1999 1987-1999
Patients 24 145 32 106 307
Hemoglobin 4/1 10/4 6/1 16/4 36/10
Leukocyte
count
13/6 36/17 12/8 37/17 98/48
Neutrophil
count
10/5 38/21 10/6 38/16 96/48
Platelet
count
6/0 29/17 5/4 16/9 56/30
Nausea/
vomiting
2/0 14/0 0/1 5/2 21/3
Alopecia 2/0 15/0 1/0 2/0 20/0
Neurologic
toxicity
1/0 7/0 0/1 7/2 15/3
Mucositis 1/0 0/0 2/0 1/0 4/0
NOTE: Differences in the distribution of the grades of toxicity among the four
groups are not statistically significant.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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(1.3%): three cases of lung carcinoma (one was synchronous,
the other two developed in patients who also had received
radiotherapy) and one colorectal cancer in a subject treated
with chemotherapy only. A second non-Hodgkin’s lymphoma
was observed in three patients (1%), all of whom had also
received radiotherapy. On the whole, 9 of 16 second tumors
arose in patients who had undergone combined chemother-
apy and radiotherapy and only in two of these nine cases
after an additional second-line chemotherapy. The median
interval between the end of initial therapy for Hodgkin’s
lymphoma and diagnosis of secondary AML/MDS was 22.4
months (range: 8-132 months). Six of the nine cases of
secondary AML or MDS occurred within 5 years from
completion of the initial therapy. The median survival after
the diagnosis of AML/MDS was 10 months (range: 8-36).
One patient developed essential thrombocytopenia 4 years
after treatment and two complained of hypothyroidism (both
were irradiated after chemotherapy and are presently taking
hormone replacement therapy).
Fertility was not specifically studied in these high-risk
patients, but was informally assessed during the routine
follow-up of the patients. However, of the 26 women who
were in the fertile age (15-45 years), were sexually active, and
did not continue contraceptive use after the end of treatment,
five normal pregnancies were recorded 2, 3, 10, 11, and 14
years after treatment; two men were also recorded to have
fathered children.
Besides being used as front-line therapy, MOPPEBVCAD was
used as a salvage regimen in 24 patients outside the 307 of this
evaluation. Most of these subjects had early-stage disease and
did not undergo high-dose chemotherapy plus peripheral
blood stem cell transplantation because of various comorbid
conditions or older age. Nine of these 24 patients had
refractory disease (two after VBM + radiotherapy, four after
CVPP + radiotherapy, and three after ABVD or EVE +
radiotherapy), whereas 15 had relapsed (5 within and 10
beyond 12 months from the end of treatment, which had been
VBM + radiotherapy in three cases, CVPP + radiotherapy
in three and ABVD or alternating MOPP/ABVD in nine).
Clinical response to this second-line MOPPEBVCAD therapy
was complete in 21 patients (nine of nine refractory ones),
partial in one, and null in two. The clinical results in this
particular setting were only slightly inferior to those recorded
in the corresponding patients in the same trials who
underwent high-dose chemotherapy followed by transplanta-
tion procedures.
Discussion
The clinical response to MOPPEBVCAD plus limited and
conditioned radiotherapy (94% CR rate) was similar or even
better than that achieved with the best and most recent
chemotherapy regimens. The CR rate obtained by MOPP/ABV
hybrid ranges from 80% (26, 27) to 83% (28), by standard
BEACOPP 88% (11), by escalated BEACOPP 96% (12), by
COPPABVD 85% (12), and by COPP/ABV/IMEP 77% (29).
These results seem to give credit to Goldie and Coldman’s
theory that underlies the strategies of hybridization and
intensification in which the drug doses of the alternating nine
cycles of CAD/MOPP/ABV were condensed and redistributed in
six cycles of MOPPEBVCAD. The actually administered 0.73
average, relative dose intensity, with respect to the planned doses
and time length of MOPPEBVCAD, correspond to a 1.12
intensification of the truly delivered doses in the original
alternating schedule. This intensification is probably the main
cause of the remarkable improvement in response with respect to
the original alternated CAD/MOPP/ABVD (78% CR rate;
ref. 13), although we must consider also the parallel 50%
increase of dose density produced by our modification. The new
regimen was found to be particularly effective despite the
decidedly reduced radiotherapy program optionally combined
with the chemotherapy. Moreover, the regimen was always
administered in different multicenter settings, which testifies to its
feasibility and gives assurance of the reproducibility of the results.
A comment is needed on the early and late toxicity related to
MOPPEBVCAD chemotherapy.
Early hematologic toxicity was remarkable but manageable.
About 32% of the patients completed the combined therapy
before growth factors were available in Italy; thereafter, they
were used, strictly on demand, in 24% of the patients treated
after 1992 when growth factors did become available. The acute
nonhematologic toxicity can be considered fully acceptable;
in particular, the administration of the three different Vinca
alkaloids incorporated in the schedule did not seem to cause a
significant price in terms of neurotoxicity.
Treatment-related mortality was low in absolute terms and
lower than that of the majority of the regimens tested for
advanced Hodgkin’s lymphoma (Table 5).
When designing MOPPEBVCAD, there was great concern
about the potential oncogenic effect of the three different
alkylating agents and one nitrosurea present in the schedule. To
reduce the risk of second tumors without lowering effective-
ness, the total dose of mechlorethamine was reduced by 50%
compared with that delivered in the original chemotherapy
program and, moreover, both the extension and doses of
radiotherapy were strongly limited. The number of second
cancers actually observed (2.9% AML/MDS, 2.3% solid tumors)
was higher than we expected from such modifications but can
be considered lower than that recorded after many other
chemotherapy regimens for advanced Hodgkin’s lymphoma
(30). The hitherto published very large, retrospective studies of
patients pooled from differently treated series are not suitable
for making reliable comparisons of the risk of the regimens
Fig.1. Kaplan-Meier analysis of theprobability ofoverall survival (OS), disease-free
survival (DFS), and failure-free survival (FFS).
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causing second cancer. In Table 5, we have listed only those
randomized trials with a sufficiently long follow-up to offer a
clear-cut incidence per treatment arm and able to show the
relationship between a single treatment and the second cancers
that arise after it.
From this point of view, the 2.9% incidence of second
AML/MDS recorded at 10 years following MOPPEBVCAD is a
true reduction with respect to incidences recorded after 5 or
6 years with many other regimens (30). Moreover, the
cumulative 10-year incidence of AML/MDS is probably a
definitive estimate because the incidence does not tend to
increase beyond 10 to 12 years after the end of treatments
(30). Similarly, the 10-year cumulative incidence of second
solid tumors after MOPPEBVCAD (2.3%) is comparable with
the percentages recorded at 5 to 6 years following the
majority of the other multiple drug regimens. In such
comparisons, the relatively high proportion of mature and
elderly patients in our series (20% >50 years of age) must be
considered because this proportion is higher than that of
most of the patient populations listed in Table 4. As it is well
known, age >45 years at diagnosis is an unfavorable
prognostic factor in Hodgkin’s lymphoma (31).
With the aim of minimizing the oncogenic potential of
MOPPEBVCAD, some modifications of this schedule have
already been tested and others are under evaluation. Probably,
the type of drugs included in the therapeutic combinations also
plays a crucial but not quantified role in these models, besides
that undeniable of drug dose size, intensity, or density. We are
not referring to the intensive and frequent use of Vinca alkaloids
in the MOPPEBVCAD, which includes vindesine, vincristine,
and vinblastine in weekly sequence in each cycle, but to the
proven role of even low doses of lomustine and melphalan. A
brief randomized trial by GISL, published in 2000 (17), tested a
possibly less toxic variant of MOPPEBVCAD, MOPPEBVCyED,
in which cyclophosphamide and etoposide replaced lomustine
and melphalan, respectively, whereas all the other drugs were
the same. This modified regimen actually showed lower early
toxicity, and the study was closed after the planned number of
patients had been treated. However, in the subsequent years of
follow-up, it was associated with a higher failure rate and with a
difference that approached the conventional levels of statistical
significance. The conclusion was that lomustine and melphalan
are decisive in the efficacy of the combination; thus, that trial did
not contribute to reducing the risk of second cancers but simply
added evidence of the effectiveness of two drugs in the schedule.
A subsequent GISL trial, started at the end of 2000 and still
ongoing, is evaluating a new modification of the schedule in
which mechlorethamine is replaced by cyclophosphamide while
all other drugs and doses are unmodified. The interim analyses
can currently only testify to the excellent effectiveness of the
regimen, obviously providing no information on its oncogenic-
ity. In the near future, positron emission tomography–aided
evaluation of the response after chemotherapy might further
restrict the criteria for the use of radiotherapy after MOPPEBV-
CAD. Moreover, in the case of radiotherapy, volumes of
radiotherapy must be made homogeneous; doses ranging from
30 to 36 Gy seem to be most suitable.
In conclusion, our experience with MOPPEBVAD with
limited radiotherapy can be summarized as follows:
 MOPPEBVCAD F radiotherapy produces excellent clini-
cal responses in patients with advanced Hodgkin’s
Table 5. Results of themainalternatingorhybrid regimens in the treatmentofadvancedHodgkin’s disease recorded in
the last15 years
Authors CT No.
patients
CR
(%)
OS
(%)
DFS
(%)
FFS
(%)
TRM
(%)
AML
(%)
SST
(%)
Median follow-up
(mo)
Connors et al. (32) MOPP/ABV hybrid 153 80 81 (5 y) NG 71 (5 y) 3 NG NG 60
MOPP/ABVDalternating 148 76 83 (5 y) NG 67 (5 y) 1 NG NG 60
Glick et al. (27) MOPP/ABVDalternating 344 75 71 (8 y) NG 54 (8 y) NG 2.6 NG 88
MOPP/ABVDhybrid 347 83 79 (8 y) NG 64 (8 y) NG 0.3 NG 88
Radford et al. (26) ChlVPP/EVA 144 62 89 (5 y) 78 (5 y) NG 3 0.7 2.7 59
VAPEC-B 138 47 79 (5 y) 58 (5 y) NG 1. 5 0 2.2 59
Horning et al. (28) StanfordV 142 NG 96 (5 y) NG 89 (5 y) 0 0 0.7 65
Canellos et al. (33) MOPP 123 NG 59 (5 y) NG 40 (10 y) NG NG NG 169
ABVD 115 NG 66 (10 y) NG 59 (10 y) NG NG NG 169
MOPP/ABVDalternating 123 NG 64 (10 y) NG 52 (10 y) NG NG NG 169
Diehl et al. (12) BEACOPP standard 469 88 88 (5 y) 76 (5 y) NG <2 0.6 2.1 54
BEACOPP, escalated 466 96 91 (5 y) 87 (5 y) NG <2 2.5 2.6 51
COPP/ABVD 260 85 83 (5 y) 69 (5 y) NG <2 0.4 2.7 72
Duggan et al. (34) ABVD 433 76 82 (5 y) NG 63 (5 y) 2.1 0.47 3.7 60
MOPP/ABV hybrid 419 80 81 (5 y) NG 66 (5 y) 3.6 2.6 4.0 60
Sieber et al. (29) COPP/ABV/IMEPhybrid 293 77 73 (7 y) NG 54 (7 y) 2.74 0.68 2.04 84
COPP/ABVD 291 78 73 (7 y) NG 56 (7 y) 3.07 2.06 1.03 84
Martinelli et al. (35) ChlVPP/ABVVPhybrid 61 95 79 (5 y) 81 (5 y) 72 (5 y) 0 1.6 NG 60
Present series MOPPEBVCAD 307 94 74 (10 y) 80 (10 y) 78 (10 y) 0.98 2.9 2.3 114
Abbreviations: OS, overall survival; DFS, disease-free survival; FFS, failure-free survival;TRM, treatment-related mortality; SST, solid second tumors; NG, not given.
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lymphoma and, at present, can be considered among the
group of combination treatments with absolutely the best
clinical performance.
 Nearly half of the patients who relapsed can be further
rescued with high-dose chemotherapies followed by bone
marrow transplantation (better) or with conventional treat-
ments (less good).
 Treatment-related mortality is near the lower range ob-
served with most of the intensive regimens for advanced
Hodgkin’s lymphoma, and early toxicity, mainly hema-
tologic, is considerable but manageable.
 Overall, failure-free and progression-free survival curves
at 10 years are among the best recorded with conventional
treatments.
 The 10-year incidence of second cancers is considerably
reduced if compared with that following analogous
treatments with similar follow-up; however, it is still
higher than that following ABVD.
 The effectiveness/second cancer ratio is slightly in favor of
the ABVD regimen, which must still be considered the
gold standard; nevertheless, MOPPEBVCAD represents a
very good second-line regimen for patients who are not
candidates for high-dose chemotherapy.
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